Stock Analysis of Adaptimmune Therapeutics Plc (ADAP) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ADAP
Close 1.11
Change -0.090 / 7.50 %
Volume 1056.66 K
Vol Change -229435.00 / 17.84 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthNeutral
Growth Index Very Low Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Very Low Stability Stock


Fundamental View of Adaptimmune Therapeutics Plc
PE (TTM)

-7084.73

Very Poor
Price / Book

15966.55

Very Poor
Price / Sales

63063.28

Very Poor
Piotroski F Score

1.0

Very Poor
Market Cap

283673 K

Enterprise Value

145066 K

ROA (TTM)

-55.64

Very Poor
ROE (TTM)

-225.37

Very Poor
Net Margin (TTM)

-890.13

Very Poor
Revenue

161.82 %

71078.00 K
Net Profit

42.46 %

-95204.00 K
Debt to Equity

0.136

Excellent
Altman Z Score

-4.67

Very Poor
Quick Ratio

2.83

Good
Cash Ratio

2.02

Good


Highs/Lows of Adaptimmune Therapeutics Plc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.12 0.893 % 1.54 % 1.341.116-May-2417-May-24
Two Week1.19 6.72 % 3.42 % 1.341.0216-May-2408-May-24
One Month0.987 12.46 % 5.60 % 1.340.872116-May-2418-Apr-24
Three Month1.2 7.50 % 5.95 % 2.050.872108-Mar-2418-Apr-24
Six Months0.479 131.73 % 17.48 % 2.050.4208-Mar-2421-Nov-23
One year1.34 17.16 % 27.52 % 2.050.4208-Mar-2421-Nov-23
Two year1.57 29.30 % 29.70 % 2.650.4214-Nov-2221-Nov-23
Five year3.67 69.75 % 85.46 % 2.650.4214-Nov-2220-Nov-23


Technical View of Adaptimmune Therapeutics Plc
RSI

44.73

Neutral
MACD

-0.0166

Bullish
ADX

12.06

Neutral
Super Trend

1.30

Mild Bearish
Williams %R

-71.87

Neutral
CCI

-19.58

Strong Bearish


EMA 5

1.16

Strong Bearish
EMA 15

1.16

Strong Bearish
EMA 50

1.20

Neutral
EMA 100

1.14

Whipsaw
SMA 100

1.18

Whipsaw
SMA 200

0.914

Mild Bullish
SMA 5 / 20

1.17 / 1.14

Bullish
SMA 15 / 50

1.16 / 1.27

Mild Bearish
SMA 50 / 200

1.27 / 0.914

Bullish




Charts of Adaptimmune Therapeutics Plc


Returns of Adaptimmune Therapeutics Plc with Peers
Period / StockADAPINZYTRHCAQST
1 Week-0.893%1.32%1.16%0.647%
1 Mth12.46%-1.08%1.25%-20.66%
3 Mth-7.50%-20.96%34.96%15.40%
6mth131.73%41.10%89.53%79.77%
1 Year-17.16%-30.83%186.10%51.71%
2 Year-29.30%10.58%-63.31%157.02%
5 Years-69.75%--86.51%-38.42%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Adaptimmune Therapeutics Plc with Peers
Ratio / StockADAPINZYTRHCAQST
PE-7084.73-1769.30-0.0268-3302.11
P/B15966.551594.53-5.46-1028.90
ROA-55.64-57.07-2504.19-39.44
ROE-225.37-78.9900
Debt To Equity0.1360.325-5.67-0.262
Revenue71078.00 K
161.82 % 		0
% 		299516 K
9.58 % 		48059.00 K
0.795 %
Net Income-95204.00 K
42.46 % 		-68169.00 K
1.65 % 		-147510.00 K
86.59 % 		-12111.00 K
77.74 %


Technicals of Adaptimmune Therapeutics Plc with Peers
Technical / StockADAPINZYTRHCAQST-
ADX12.0625.8362.6019.22
CMF-0.065-0.240-0.02670.0029
MFI52.0658.8453.6033.44
RSI44.7342.6775.1439.25
MACD Abv SignalTrueTrueFalseFalse
Price Above 50 MAFalseFalseTrueFalse-
Price Above 200 MATrueFalseTrueTrue-


About : Adaptimmune Therapeutics Plc

Address : 60 Jubilee Avenue, Abingdon, United Kingdom, OX14 4RX
Tel : 44 12 3543 0000
URL : https://www.adaptimmune.com
Code : ADAP, ISIN : US00653A1079, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 06_May_2015
Employee Count : 449

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.


Note : All Data Generated at the End of Trading Hours (EOD Data)